Cybercriminals Leverage Infostealer Malware to Harvest 1.7 Billion Credentials

A groundbreaking immunotherapy, termed immunoablative therapy, has shown remarkable success, with 84 out of 100 participants experiencing complete cancer remission. This treatment focuses on patients with a specific genetic mutation, called mismatch repair deficiency, which enhances their response to the therapy using a humanized mouse antibody known as dostarlimab. According to the research published in the New England Journal of Medicine, 80% of participants, who had cancer types such as esophageal, stomach, colon, liver, bladder, uterus, and prostate cancers, saw their tumors vanish.
Patients like 71-year-old Maureen Sideris, who was diagnosed with gastroesophageal cancer, report feeling rejuvenated post-treatment. Sideris remarked, “The cancer has disappeared in my PET images and biopsies,” while oncologist Luis Alberto Díaz emphasized the therapy’s potential to spare patients from more aggressive treatments like chemotherapy and surgery. The therapy costs approximately $55,000 per patient, but Díaz notes it can ultimately reduce overall healthcare costs. Researchers stress that long-term benefits are still being evaluated, particularly for non-rectal cancer cases.